NCT00352183已完成3 期
A Multicenter, Double-Blind, Randomized Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Simvastatin Alone.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 450
- 试验地点
- 67
- 主要终点
- Triglycerides
研究概览
简要总结
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Mixed dyslipidemia
排除标准
- •Diabetes,
- •Known hypersensitivity to fenofibrate or simvastatin,
- •Pregnant or lactating women,
- •Contra-indication to fenofibrate or simvastatin,
- •Unstable or severe cardiac disease.
研究组 & 干预措施
1
Experimental
干预措施: Fenofibrate/Simvastatin (Drug)
2
Active Comparator
干预措施: Simvastatin (Drug)
结局指标
主要结局
Triglycerides
时间窗: 12 weeks
Percent change from baseline to 12 weeks of treatment in HDL-C
时间窗: 12 weeks
Percent change from baseline to 12 weeks of treatment in LDL-C
时间窗: 12 weeks
次要结局
- Percent change from baseline to 24 weeks of treatment in Triglycerides(24 weeks)
- Percent change from baseline to 24 weeks of treatment in HDL-C(24 weeks)
- Percent change from baseline to 24 weeks of treatment in LDL-C(24 weeks)
研究者
研究点 (67)
Loading locations...
相似试验
已完成
3 期
Comparison of the Combination of Fenofibrate and Simvastatin Versus PravastatinHyperlipidemiaNCT00362206Solvay Pharmaceuticals423
已完成
3 期
Comparison of the Combination of Fenofibrate and Simvastatin Versus AtorvastatinHyperlipidemiaNCT00362934Solvay Pharmaceuticals516
已完成
3 期
Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin MonotherapyHyperlipidemiaNCT00349375Solvay Pharmaceuticals1,040
已完成
3 期
Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)Primary HypercholesterolemiaMixed DyslipidemiaNCT00479388Merck Sharp & Dohme LLC1,216
已完成
不适用
A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.Complex DyslipidemiaNCT02382159Yooyoung Pharmaceutical Co., Ltd.1,000